

## NCI FACILITY OVERVIEW

### Advanced Technology Research Facility

- 332,088 Square-foot facility situated on a 32 acre campus
- Structure houses some of the world's most advanced laboratory space; a cGMP validated manufacturing facility and Class A Office space
- Opportunity for build-to-suit space co-located near the nation's oldest and largest institute
- Advanced Technology Partnerships Initiative
- Mission to accelerate new discoveries, diagnostics and therapeutics to Cancer and AIDS patients
- Public and private partnership opportunities available to work with some of the world's best scientific minds
- A translational research enterprise that can rapidly and cost-effectively transition research discoveries into products for cancer patients

### Partnerships

Progress is being made in the fight against cancer and AIDS through the mission of the Advanced Technologies Partnership Initiative. Many partnership agreements have been formed across the wide range of programs and technologies of NCI-Frederick.

### Participating firms include:

- |                                |                             |
|--------------------------------|-----------------------------|
| • Amplimmune, Inc.             | • Fluidigm Corporation      |
| • Applied Research & Photonics | • Geospiza                  |
| • Bexion Pharmaceuticals       | • GNS Healthcare            |
| • Biomatrix                    | • Mayo Clinic               |
| • Celator Pharmaceuticals      | • RemedyMD, Inc.            |
| • EGEN Inc.                    | • SAIC-Frederick            |
|                                | • Sporian Microsystems Inc. |



# NATIONAL CANCER INSTITUTE

## FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH



JOIN THE TEAM. **SHARE THE VISION.**

## NCI PARTNERSHIPS

### Advanced Technologies Partnership Initiative

Many partnership agreements have been formed across the wide range of programs and technologies of NCI-Frederick. The following is a list of recent agreements.

**EGEN Inc.** is collaborating with the **National Cancer Institute's Nanotechnology Characterization Laboratory** in Frederick, Md., to accelerate human clinical testing of a nanotechnology-based gene therapy for brain cancer.

**SAIC-Frederick, Inc. and RemedyMD, Inc.** announced an agreement to implement RemedyMD's Investigate™ Integrated Research Management System software at the National Cancer Institute (NCI) Advanced Technology Program in Frederick, Md. The software is designed to help manage and analyze large amounts of research data to accelerate progress against cancer.

**GNS Healthcare, Inc.** is collaborating with the **National Cancer Institute (NCI)** to accelerate lung cancer research with a supercomputing platform that can rapidly uncover cause-and-effect mechanisms hidden in huge data sets assembled from imaging, genetics, pathology, and other areas. The results could help predict which patients will respond to a given treatment.

**SAIC-Frederick and Biomatrix** have begun a technology collaboration to improve molecular analysis of tumors, which is becoming increasingly important in cancer research and in the design of the next generation of targeted therapies.

**Bexion Pharmaceuticals** announced that it has been selected by the National Cancer Institute (NCI) for a research collaboration to study Bexion's first-in-class cancer nanotherapy treatment for solid tumors. The research will be conducted by the **NCI's Nanotechnology Characterization Laboratory (NCL)**, part of a major program, the Alliance for Nanotechnology in Cancer, to advance the medical applications of nanotechnology.

**SAIC-Frederick And Fluidigm Corporation** are collaborating to decode the entire genome of the Epstein-Barr virus (EBV) using technology that can speed up research on the genetic basis of cancer and other diseases.

**Celator® Pharmaceuticals** announced that the **National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL)**, operated by SAIC-Frederick, has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology.

**Applied Research & Photonics (ARP) and SAIC-Frederick, Inc.** have entered into a collaboration to assess a new technology – terahertz spectrometry – for analysis of structures and materials supporting biopharmaceutical manufacturing.

**The National Cancer Institute** and its operations and technical support contractor **SAIC-Frederick, Inc.** have entered into a research and development collaboration with **Mayo Clinic** to expand on recent research discoveries at Mayo, where researchers have demonstrated the importance of a key protein involved in pancreatic and lung cancer.

**SAIC-Frederick, Inc.**, a contractor to the National Cancer Institute, has entered into a three-way research collaboration with **Sporian Microsystems Inc.** of Lafayette, CO, and the **Food and Drug Administration (FDA)** centering on a hand-held device for HIV testing that could potentially be used to improve screening in remote areas.

**Geospiza and SAIC-Frederick, Inc.** are collaborating to adapt Geospiza's software platform to a new generation of rapid, high-resolution gene sequencing technology to potentially accelerate cancer research and help develop new treatments.

**Amplimmune, Inc.**, has entered into a broad agreement with the **National Cancer Institute (NCI)** for further advancement of two Amplimmune product candidates into therapies for cancer and autoimmune disease.